Abstract
Background: Biotechnology, which promoted revolutions in many fields, generates great expectations for the future, mainly in the pharmaceutical sector for the treatment of several diseases. Cancer is a leading cause of death worldwide and due to its complexity and singularity, there are a number of challenges that limit the development of new drugs for antitumor therapies, making the research for cancer treatment one of the most exploited in the medical field. Objective: The main objective of this article is to identify trends of biotechnological advances that may have application in improving cancer therapies. Method: Information from patent applications of biotechnological drugs in the last five years was retrieved using Thomson Reuters Integrity database. Results: Cancer is the leading therapeutic condition found in patent documents. The subject matter most cited in patent applications includes monoclonal antibodies, adoptive cell therapy, RNA interference and new vaccine peptides. Conclusion: The analysis of the documents has provided an overview of new biological alternatives for use in cancer treatment, showing potential avenues for years to come.
Keywords: Antibodies, biotechnology, cancer, patents, peptides, proteins, RNAi, vaccine.
Recent Patents on Anti-Cancer Drug Discovery
Title:Trends in Biotechnological Drugs for Cancer Treatment
Volume: 11 Issue: 1
Author(s): Natalia L. von Ranke, Iolanda M. Fierro and Adelaide M.S. Antunes
Affiliation:
Keywords: Antibodies, biotechnology, cancer, patents, peptides, proteins, RNAi, vaccine.
Abstract: Background: Biotechnology, which promoted revolutions in many fields, generates great expectations for the future, mainly in the pharmaceutical sector for the treatment of several diseases. Cancer is a leading cause of death worldwide and due to its complexity and singularity, there are a number of challenges that limit the development of new drugs for antitumor therapies, making the research for cancer treatment one of the most exploited in the medical field. Objective: The main objective of this article is to identify trends of biotechnological advances that may have application in improving cancer therapies. Method: Information from patent applications of biotechnological drugs in the last five years was retrieved using Thomson Reuters Integrity database. Results: Cancer is the leading therapeutic condition found in patent documents. The subject matter most cited in patent applications includes monoclonal antibodies, adoptive cell therapy, RNA interference and new vaccine peptides. Conclusion: The analysis of the documents has provided an overview of new biological alternatives for use in cancer treatment, showing potential avenues for years to come.
Export Options
About this article
Cite this article as:
von Ranke L. Natalia, Fierro M. Iolanda and Antunes M.S. Adelaide, Trends in Biotechnological Drugs for Cancer Treatment, Recent Patents on Anti-Cancer Drug Discovery 2016; 11 (1) . https://dx.doi.org/10.2174/1574892810666150928160202
DOI https://dx.doi.org/10.2174/1574892810666150928160202 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Patent Selections
Recent Patents on Regenerative Medicine MiRNA-29: A microRNA Family with Tumor-Suppressing and Immune-Modulating Properties
Current Molecular Medicine Targeting ATP7A to Increase the Sensitivity of Neuroblastoma Cells to Retinoid Therapy
Current Cancer Drug Targets A Brief Evaluation of Tumor Imaging in Mice with 99mTc-glucarate Including a Comparison with 18F-FDG
Current Radiopharmaceuticals Treatment of Chronic Hypercalcemia
Medicinal Chemistry Use of Intravenous Immunoglobulin in the Treatment of Immune-Mediated Demyelinating Diseases of the Nervous System
Current Pharmaceutical Design A Review on Noscapine, and its Impact on Heme Metabolism
Current Drug Metabolism Nanomedical Applications of Amphiphilic Dendrimeric Micelles
Current Medicinal Chemistry Evolution of Reactive mPEG Polymers for the Conjugation of Peptides and Proteins
Current Organic Chemistry Emerging Therapies in the Treatment of Locally Advanced Squamous Cell Cancers of Head and Neck
Recent Patents on Anti-Cancer Drug Discovery Mini-Review: Nucleus-Targeted Ribonucleases As Antitumor Drugs
Current Medicinal Chemistry Glioma Stem Cell Maintenance: The Role of the Microenvironment
Current Pharmaceutical Design Effect of MRJF4 on C6 Glioma Cells Proliferation and Migration
Central Nervous System Agents in Medicinal Chemistry Liposome-Nanogel Structures for Future Pharmaceutical Applications: An Updated Review
Current Pharmaceutical Design Brain Targeted Drug Delivery: Factors, Approaches and Patents
Recent Patents on Nanomedicine Tumour-Specific Uptake of Anti-Cancer Drugs: The Future is Here
Current Drug Metabolism pH-Gradient Incorporation of 9-Nitrocamptothecin in PEGylated Liposomes: Formulation Properties and Efficacy <i>In Vitro</i> and <i>In Vivo</i>
Pharmaceutical Nanotechnology Berberine as a Promising Safe Anti-Cancer Agent- Is there a Role for Mitochondria?
Current Drug Targets Lessons in Medical Record Abstraction from the Prostate, Lung, Colorectal, and Ovarian (PLCO) National Screening Trial
Reviews on Recent Clinical Trials Cellomics as Integrative Omics for Cancer
Current Proteomics